Phase II clinical study of Aimmune's AR201 for egg allergy completed the first patient randomized group

Recently, Aimmune Therapeuticscompany(http://announced that the first phase II clinical study to evaluate AR201 for egg allergy has been completedAR201 is a biological drug that treats egg allergies through oral immunity and is the second development project to be promoted to Phase II clinical using Aimmune's proprietary oral desensitization immunotherapy (CODIT) platformAR201 is a clinically developed research biologic drug used for oral immunotherapy for egg allergiesAimmune is conducting extensive research on AR201 to make this potential therapy widely availableAimmune has reached an exclusive
supply of egg protein to Michael Foods, the largest high-value-added egg processor in the United States
http://The agreement includes all of Michael Foods' egg products worldwide and grants Aimmune the exclusive rights to obtain Michael's egg products for clinical and commercial use for up to 15 years after the potential regulatory approval of AR201 for any egg allergy treatment, prevention or cure
Aimmune Therapeutics is a bio
pharmaceuticalpharmaceutical(http:// company focused on developing innovative therapies to treat potentially life-threatening food allergies